- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | - | SEC Filings | ||
| 27.12.24 | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.24 | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.12.24 | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.24 | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus | 2 | GlobeNewswire (USA) | ||
| 21.11.24 | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group | 92 | GlobeNewswire (Europe) | PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on innovative therapies for serious... ► Artikel lesen | |
| LIPELLA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.11.24 | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform | 3 | GlobeNewswire (USA) | ||
| 05.11.24 | Lipella Pharmaceuticals-Aktie erreicht 52-Wochen-Tief bei 0,32 US-Dollar | - | Investing.com Deutsch | ||
| 05.11.24 | Lipella Pharmaceuticals stock hits 52-week low at $0.32 | 5 | Investing.com | ||
| 01.11.24 | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.11.24 | Lipella Pharmaceuticals announces 1-for-8 reverse stock split | 1 | Investing.com | ||
| 01.11.24 | Lipella Pharmaceuticals kündigt Aktienzusammenlegung im Verhältnis 1:8 an | 1 | Investing.com Deutsch | ||
| 01.11.24 | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split | 110 | GlobeNewswire (Europe) | PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the "Company," "our" or "us"), a clinical-stage biotechnology company focused on developing innovative therapies... ► Artikel lesen | |
| 18.10.24 | Lipella Pharmaceuticals droht Delisting von der Nasdaq aufgrund von Eigenkapitalmangel | 1 | Investing.com Deutsch | ||
| 18.10.24 | Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall | 1 | Investing.com | ||
| 18.10.24 | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.10.24 | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform | 151 | GlobeNewswire (Europe) | Patent application covers key technology innovations for delivering therapeutic agentsProprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship... ► Artikel lesen | |
| 09.10.24 | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 24.09.24 | Lipella reports positive phase 2a trial results for OLP treatment | 1 | Investing.com | ||
| 11.09.24 | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,400 | +2,94 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,426 | +3,65 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,300 | 0,00 % | Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors | Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics
... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,330 | 0,00 % | CEO von Recursion Pharmaceuticals verkauft Aktien im Wert von 287.200 US-Dollar | ||
| BEAM THERAPEUTICS | 23,320 | 0,00 % | Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts | More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,790 | -3,07 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,525 | 0,00 % | Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 8.6% - Here's Why | ||
| ASSERTIO | 0,786 | 0,00 % | Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,320 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 10,255 | 0,00 % | Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why | ||
| SIGA TECHNOLOGIES | 6,335 | 0,00 % | SIGA Technologies Inc.: TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses | Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,260 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,650 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| QUANTUM-SI | 2,030 | 0,00 % | Quantum-Si (NASDAQ:QSI) Given Buy Rating at HC Wainwright | ||
| TRAVERE THERAPEUTICS | 17,400 | +4,82 % | Travere Therapeutics, Inc. - 8-K, Current Report |
LIPELLA PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIPELLA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
